Skip to main content

Table 1 MIC and MBC of P128 against 32 Staphylococcus aureus strains

From: Antistaphylococcal activity of bacteriophage derived chimeric protein P128

Sl. No.

Strain

MIC (μg/mL)

MBC (μg/mL)

1

BK#13725

2

2

2

BK#9894

2

4

3

BK#2926 (USA100)

2

8

4

BK#13993

4

4

5

BK#14035

4

16

6

BK#12003

4

16

7

BK#13385

4

32

8

BK#15273

4

4

9

BK#14942

4

4

10

BK#19069 (USA300)

4

8

11

BK#11147

4

4

12

BK#15271

4

4

13

BK#14483

4

> 32

14

BK# 13387

4

8

15

BK#13228

8

8

16

BK#14935

8

16

17

BK# 13237

8

32

18

BK#14655

8

8

19

BK#18552

8

16

20

BK#9897 C (USA400)

8

8

21

BK#14284

16

16

22

BK#13180

16

16

23

BK#8374 (COL)

16

64

24

BK#11512

16

16

25

BK#11433

16

16

26

BK#13641

16

64

27

BK#2394

32

64

28

BK#9918

1

1

29

BK#14780

8

8

30

BK#15383

16

16

31

USA500/1

16

ND

32

USA500/2

64

ND

33

S. carnosus, ATCC 51365

0.5

0.5

34

S. aureus, ATCC 25923

4

4

  1. MIC was determined using a modification of the CLSI broth microdilution method. P128 was tested at 256 to 0.125 μg/mL. S. aureus ATCC 25923 and S. carnosus ATCC 51365 were used as control strains. MBC was determined following the CLSI procedure by plating 100 μL from the MIC, MIC × 2, MIC × 4, and MIC × 8 wells on LB agar, and incubating the plates overnight at 37°C. Strains 1-30 constitute a global panel of distinct clinical isolates (MRSA, strains1-27; MSSA, strains 28-30) obtained from the Public Health Research Institute (NJ, USA); strains 31 and 32 are USA500.